The Sustained Virologic Response and Adverse Effects of Peg Interferon Alfa and Ribavirin in the Treatment of Patients with Chronic Hepatitis C: A Study from Iran

Simindokht Shoaei, Shahnaz Sali, Azadeh lali, Mehdi Karamipour, Javad Minooeefar

269

Abstract

Background: Hepatitis C infection is a worldwide problem. In Iran, hepatitis C virus (HCV) infection prevalence is about 1-2%. A combination therapy of pegylated interferon alfa-2a and ribavirin (PEG-IFNa/RBV) is a standard treatment, but our aim was to determine the efficacy and safety of dual PEG-IFNa/RBV therapy in treating patients infected with HCV in Iranian context.

Materials and Methods: This study is a cross sectional conducted among 98 HCV infected patients who were admitted to Labbafinezhad Hospital (Tehran, Iran) for treatment from April 2014 to September 2016. Patients were medicated with Peg Interferon Alfa (INFα) and Ribavirin (RBV). Lab tests were monitored through the study and dose modification was done. We also assessed treatment responses at the defined time points. The incidences of adverse events were determined either. We investigated independent predictors of sustained virologic response (SVR) in the participants. Finally, data were gathered and statistical analysis was completed.

Results: Eighty-eight percent of patients were male and 11.2% were female. Mean age was 43.44 years. Patients were mostly male, single, with nongovernmental business and low level of education. Risk factors were known to be addiction with non-injectable substances and phlebotomy. Myalgia, fatigue and malaises were the most common complications and suicide intention was the least one. SVR was estimated 76.7%. AST and ALT were significantly reduced in treatment period.

Conclusion: Peg INFα and RBV are effective in treating HCV infection.

Keywords

Hepatitis C, Ribavirin, Peginterferon, Sustained virological response

Full Text:

PDF

References

Mas-Coma S, Bargues M D. Human liver flukes: A review. Research and Reviews in Parasitology.1997; 57: 145–218.

Boray J C. Fasciolosis. In: Hillyer GV, Hopla CE (Eds) Handbook Series in Zoonoses, Vol. III. CRC, Boca Raton- Florida. 1982;pp 71–88.

Chen M G & Mott K E. Progress in assessment of morbidity due to Fasciola hepatica infection: a review of recent literature. Tropical diseases bulletin. . 1990; 87(4): 1-38.

Mas-coma S, Valero M A, Bargues MD. Chapter2 Fasciola, Lymnaeids and human fascioliasis with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Advances in Parasitology. 2009; 69:41-146

Ashrafi K , Valero M A , Panova M , Periago M V, Massoud J, Mas-Coma S. Phenotypic analysis of adults of Fasciola hepatica, Fasciola gigantica and intermediate forms from the endemic region of Gilan, Iran. Parasitology International. 2006; 55: 249–260

Ashrafi K, Massoud J , Holakouie K , Jo-Afshani MA, Mahmoodi M , Ebadati N, Rezvani, Artigas P, Bargues MD, Mas-coma S. Nuclear ribosomal DNA ITS-2 sequence characterization of Fasciola hepatica and Galba trancatula. Iranian Journal of Public Health. 2007 ; 36(4): 42-49

Gradwohl, S. Clinical Laboratory Methods and Diagnosis, 7th Edition. The CV Mosby Company, St. Louis, Toronto, London. 1970; p: 1764

Valero MA, Panova M, Mas-Coma S. Development differences in the uterus of Fasciola hepatica between livestock liver fluke populations from Bolivian highland and European lowlands Parasitology Research. 2001; 87: 337–342

Dar Y, Vignoles P, Dreyfuss G, Rondelaud D. Fasciola hepatica and Fasciola gigantica: comparative morphometric studies on the redial stage of both species. Parasitology Research. 2003; 91: 369–373

Lotfy W M, El-Morshedy H N, Abou El-Hoda M, El-Tawila, Omar E A , Farag HF..Identification of the Egptian species of Fasciola.Veterinary Parasitology. 2002; 103: 323-332

Assmar M, Milaninia A, Amirkhani A, Yadegari D, Forghanparast K, Nahravanian H, Piazak N, Esmayli A, Hovanesian A, Aj Valadkhani Za. Seroepidemiological investigation of fascioliasis in northern Iran. Medical Journal of the Islamic Republic of Iran. 1991 ; 15;5(1):23-7.

Hosseini S H, Vaezi V, Jafari G, Rezaei A, Carami G. Epidemiological study of Fasciolosis in Kermanshah Province. Journal of Veterinary Faculty, University of Tehran. 2004; 59(3) : 201-206

Salahimoghaddam A. Epidemiology of Human Fascioliasis in Iran. Journal of Kerman University of Medical Science, 2009; 16(4):385-394

Hatami H, Asmar M, Masoud J , Mansouri F, Namdaritabar H and Ramazankhani A. The first epidemic and new-emerging human fascioliasis in Kermanshah(western iran) and ten-year follow up, 1998-2008. International Journal of Preventive Medicine. 2012; 3(4):266-272.

Ashrafi K, Bargues MD, O'Neill S, Mas-Coma S. Fascioliasis: A worldwide parasitic disease of importance in travel medicine. Travel medicine and infectious disease. 2014 Dec 31;12(6):636-49.

Eslami A. Veterinary Parasitology, Tehran University Press. 2006 ; pp: 840-844.

Valero MA, Marcos MD, Mas-Coma S-A. Mathematical model for the ontogeny of Fasciola hepatica in the definitive host. Research and Reviews in Parasitology.1996; 56:13–20.

Valero M A, Panova M, Mas-Coma S. Phenotypic analysis of adults and eggs of Fasciola hepatica by computer image analysis system. Journal of Helminthology. 2005; 79: 217–225.

Periago M V, Valero M A, El Sayed M, Ashrafi K, El Wakeel A, Mohamed MY, Desquesnes M, Curtale F, Mas-Coma S. First phenotypic description of Fasciola hepatica/Fasciola gigantica intermediate forms from the human endemic area of the Nile Delta, Egypt. Infection, Genetics and Evolution. 2008;8: 51–58.

Mas-Coma, S. Epidemiology of fascioliasis in human endemic areas. Journal of Helminthology. 2005; 79: 207–216.

Valero M A, Darce N A, Panova M, Mas-Coma S. Relationships between host species and morphometric patterns in Fasciola hepatica adults and eggs from the Northern Bolivian Altiplano hyperendemic region. Veterinary Parasitology. 2001a:102: 85–100.

Bargues MD, Mas-Coma S . Reviewing lymnaeid vectors of fasciolosis by ribosomal DNA sequence analyses. Journal of Helminthology. 2001a;79:257–267

Periago M V, Valero M A, Panova M, Mas-Coma S. Phenotypic comparison of allopatric populations of Fasciola hepatica and Fasciola gigantica from European and African bovines using a computer image analysis system (CIAS). Parasitology Research. 2006; 99: 368–378.

Ashrafi K , Valero M A , Peixoto R V, Artigas P, Panova M , Mas-Coma S. Distribution of Fasciola hepatica and F. gigantica in the endemic area of Guilan, Iran: Relationships between zonal overlap and phenotypic traits. Infection, Genetics and Evolution. 2015; 31 :95–109.

Rokni MB, Mirhendi H, Mizani A, Mohebali M, Sharbatkhori M, Kia EB, Abdoli H, Izadi S. Identification and differentiation of Fasciola hepatica and Fasciola gigantica using a simple PCR-restriction enzyme method. Experimental parasitology. 2010 Feb 28;124(2):209-13.